Roivant and its spinout Priovant made a groundbreaking announcement on Friday regarding their immune-modifying drug brepocitinib. The drug has shown significant success in clearing lesions caused by a rare skin disease in a small trial, outperforming expectations set by executives and researchers.
In a study involving 31 patients with cutaneous sarcoidosis, those who received a high dose of brepocitinib experienced a remarkable improvement in disease activity. On a scale of 165 points measuring disease severity, patients on the drug saw an average improvement of 22.3 points, while those on a placebo only showed a minimal improvement of 0.7 points. These results exceeded the initial expectations, as executives had indicated they would be satisfied if the drug outscored placebo by just five points.
Lead investigator Misha Rosenbach, director of the cutaneous sarcoidosis program at the hospital of the University of Pennsylvania, expressed his excitement over the results. He stated, “The topline of the message I would want to convey is: You could not see better results in the drug. If the drug worked half as well and had twice as many side effects, this would still be a landmark study.”
The success of brepocitinib in treating cutaneous sarcoidosis is a significant milestone in the field of dermatology. The drug’s efficacy in clearing lesions and improving disease activity offers new hope for patients suffering from this rare skin condition. The promising results of this trial pave the way for further research and development in the treatment of skin diseases.
For more in-depth analysis and exclusive content, including newsletters, premium events, and news alerts, subscribers can access the full article on STAT+. Don’t miss out on the latest updates and breakthroughs in the medical industry – subscribe to STAT+ today.
